可生物降解的多糖醇结合了抗氧化活性和硫化诱导的补充抑制
Hanna Koeppe1, Daniel Horn1, Jens Dernedde2
1Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Biomacromolecules
|December 11, 2025
概括
新的多糖醇共聚合物提供生物降解性和抗氧化特性. 硫酸盐版本显示出通过抑制补体激活来治疗与氧化压力相关的炎症的潜力.
科学领域:
- 聚合物化学 聚合物化学
- 生物材料科学 生物材料科学
- 药用化学 医学化学
背景情况:
- 多糖醇平台对于聚合物疗法具有价值,因为它们具有固有的多功能性和生物相容性.
- 引入生物降解性和抗氧化特性增强了多糖醇的治疗潜力.
- 具有和功能的循环共体是修改多糖醇骨干的关键.
研究的目的:
- 合成具有生物降解性和抗氧化功能的新型高分支多糖醇共聚物.
- 将这些共聚合物与硫酸盐组功能化,以探索它们在调节炎症反应方面的潜力.
- 评估开发材料的细胞兼容性,抗氧化活性和补充抑制作用.
主要方法:
- 甘醇与1,4-oxathiepan-7-one (GOTO) 或 thiodiglycolic anhydride (GTA) 的阳离子环开放共聚合.
- 同聚合物分子重量,共聚合物合并和水溶性的表征.
- 硫化共聚合物产生GOTO-S和GTA-S,然后评估硫化程度.
- 对细胞相容性,体外抗氧化活性 (ABTS测定) 和补充激活抑制的评估.
主要成果:
- 超分支的多糖醇共聚合物 (GOTO和GTA) 具有10kDa分子量和10mol%的共聚物合并成功合成,保持水溶性.
- 硫酸衍生物 (GOTO-S和GTA-S) 呈现出很高的硫化程度.
- 所有合成的共聚合物在生理条件下都表现出良好的细胞相容性和生物降解性.
- 观察到显著的抗氧化活性,归因于乙烯组,GTA显示最强的激素清理能力.
- 硫酸衍生物有效抑制了补体激活,其效力与已知的抗凝剂 (如dPGS和肝素) 相当.
结论:
- 新的可生物降解和抗氧化多糖醇共聚合物是通过结合循环乙烯/乙烯共体而开发的.
- 硫酸多糖醇衍生物表现出强大的补充抑制活性,表明治疗潜力.
- 这些材料对针对氧化应激相关炎症状况的应用具有前景.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
183
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
183
Drug Metabolism: Phase II Reactions
4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K


